Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CAPOX + Bevacizumab + Cetuximab in Metastatic Colorectal Cancer
NCT00290615Phase 2Completed
- Sponsor
- Herbert Hurwitz
- Start
- Jan 2006
- Primary completion
- Jan 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, bevacizumab and cetuximab in colorectal cancer (CRC), sponsored by Herbert Hurwitz. Primary endpoint: Response Rate at 24 months. Started Jan 2006; status: completed.
02
Drugs
capecitabineoxaliplatinbevacizumabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00290615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290615.